Headache News and Research

Latest Headache News and Research

New device can detect cyanide exposure within 70 seconds

A victim of cyanide poisoning can die within 30 minutes. The diagnostic test to determine cyanide exposure takes 24 hours.

13 Mar 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

electroCore’s gammaCore device effective in helping patients prevent, treat cluster headache

A twelve-month open-label study in the March issue of the journal Neurology, reports that electroCore’s non-invasive Vagus Nerve stimulation (nVNS) device, gammaCore, is practical and effective as an acute and preventative treatment in cluster headache. Seventy-nine percent of patients who completed the trial (15 out of 19) reported an overall improvement in their condition.

5 Mar 2015

Dengue fever circulating in urban areas of West Africa

Misdiagnosis of febrile illnesses as malaria is a continuing problem in Africa. A new study shows that in Ghana, dengue fever is circulating in urban areas and going undiagnosed. The authors of the study hope to use the findings to launch a widespread initiative to better understand acute undifferentiated febrile illnesses in West Africa.

3 Mar 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase III trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas.

24 Feb 2015

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists are trying to deliver a stern wake-up call to the parasite that causes sleeping sickness.

24 Feb 2015

Virus that causes chicken pox and shingles linked to giant cell arteritis

A new study developed at the University of Colorado School of Medicine at the Anschutz Medical Campus links the virus that causes chicken pox and shingles to a condition that inflames blood vessels on the temples and scalp in the elderly, called giant cell arteritis.

20 Feb 2015

New study links chicken pox and shingles virus to giant cell arteritis in elderly

A new study links the virus that causes chicken pox and shingles to a condition that inflames blood vessels on the temples and scalp in the elderly, called giant cell arteritis. The study is published in the February 18, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. The condition can cause sudden blindness or stroke and can be life-threatening.

19 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

Tips to help manage migraine in children

Although we may think of migraine as a disease of adults, it can also affect children of all ages. Some studies show migraine affects 6% of children and up to 28% of adolescents ages 15-17. To assist parents whose children suffer from migraine, and to help the children themselves, the American Migraine Foundation and its Chair, David W. Dodick, MD, FRCP (C) are offering a number of tips to help manage childhood migraine and minimize its impact.

12 Feb 2015

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

Diamond Headache Clinic's Alexander Feoktistov named recipient of 2015 NHF Lectureship

The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.

11 Feb 2015

Sign/symptom-based measures could help patients receive timely care

An examination of process measures endorsed by the National Quality Forum finds that these measures focus predominantly on management of patients with established diagnoses, and that quality measures for patient presenting symptoms often do not reflect the most common reasons patients seek care, according to a study in the February 3 issue of JAMA.

9 Feb 2015

Epidemiologist urges people to get vaccinated against measles

Americans may be victims of their own success when it comes to the eradication of infectious diseases and take their disease-free lives for granted, says Jorge Parada, MD, hospital epidemiologist and medical director of the Infection Prevention and Control program at Loyola University Health System.

4 Feb 2015

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

electroCore’s non-invasive vagus nerve stimulation therapy safe, effective across a variety of conditions

Non-invasive vagus nerve stimulation (nVNS) ‘improves the safety and tolerability of VNS making it more accessible and facilitating further investigations across a wide range of uses when compared with surgically implanted VNS’ according to a review in the European Journal of Neurology.

29 Jan 2015

AHS provides updated assessment of treatments for acute migraine

The January issue of the American Headache Society journal Headache provides an updated assessment of the best treatments to use when a migraine attack occurs. The assessment will form the basis of new AHS treatment guidelines.

21 Jan 2015

Headache News and Research

Latest Headache News and Research

New device can detect cyanide exposure within 70 seconds

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

electroCore’s gammaCore device effective in helping patients prevent, treat cluster headache

Dengue fever circulating in urban areas of West Africa

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virus that causes chicken pox and shingles linked to giant cell arteritis

New study links chicken pox and shingles virus to giant cell arteritis in elderly

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Tips to help manage migraine in children

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

Diamond Headache Clinic's Alexander Feoktistov named recipient of 2015 NHF Lectureship

Sign/symptom-based measures could help patients receive timely care

Epidemiologist urges people to get vaccinated against measles

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

electroCore’s non-invasive vagus nerve stimulation therapy safe, effective across a variety of conditions

AHS provides updated assessment of treatments for acute migraine

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in